A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

NCT06282991 · clinicaltrials.gov ↗

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Carcinoma

Interventions

DRUG: Lorlatinib

Sponsor

Pfizer